(19)
(11) EP 4 053 128 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 2 (W2 B1)

(48) Corrigendum issued on:
20.11.2024 Bulletin 2024/47

(45) Mention of the grant of the patent:
21.08.2024 Bulletin 2024/34

(21) Application number: 22152688.2

(22) Date of filing: 12.12.2018
(51) International Patent Classification (IPC): 
C07D 487/04(2006.01)
A61P 35/00(2006.01)
 A61K 31/519(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 487/04; A61P 35/00

(54)

5-(2-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER

5-(2-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE DERIVATE UND ÄHNLICHE VERBINDUNGEN ALS TRK KINASE INHIBITOREN ZUR BEHANDLUNG VON KREBS

DÉRIVÉS DE 5-(2-(2,5-DIFLUOROPHÉNYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE ET COMPOSÉS SIMILAIRES EN TANT QU'INHIBITEURS DE KINASE TRK POUR LE TRAITEMENT DU CANCER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 15.12.2017 US 201762599490 P

(43) Date of publication of application:
07.09.2022 Bulletin 2022/36

(62) Application number of the earlier application in accordance with Art. 76 EPC:
18836977.1 / 3724191

(73) Proprietor: Biohaven Therapeutics Ltd.
Tortola VG1110 (VG)

(72) Inventors:
  • PAL, Kollol
    Massachusetts, 02492 (US)
  • CIBLAT, Stephane
    Québec, H2Y 1S2 (CA)
  • ALBERT, Vincent
    Québec, J0P 1P0 (CA)
  • BRUNEAU-LATOUR, Nicolas
    Québec, J0P 1N0 (CA)
  • BOUDREAULT, Jonathan
    Québec, J7V 8T7 (CA)

(74) Representative: HGF 
HGF Limited 1 City Walk
Leeds LS11 9DX
Leeds LS11 9DX (GB)


(56) References cited: : 
WO-A1-2016/097869
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).